MX390941B - Combinacion farmaceutica que comprende ponesimod. - Google Patents

Combinacion farmaceutica que comprende ponesimod.

Info

Publication number
MX390941B
MX390941B MX2019010874A MX2019010874A MX390941B MX 390941 B MX390941 B MX 390941B MX 2019010874 A MX2019010874 A MX 2019010874A MX 2019010874 A MX2019010874 A MX 2019010874A MX 390941 B MX390941 B MX 390941B
Authority
MX
Mexico
Prior art keywords
ponesimod
pharmaceutical combination
combination including
active ingredient
teriflunomide
Prior art date
Application number
MX2019010874A
Other languages
English (en)
Spanish (es)
Other versions
MX2019010874A (es
Inventor
Laetitia Pouzol
Martine Clozel
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MX2019010874A publication Critical patent/MX2019010874A/es
Publication of MX390941B publication Critical patent/MX390941B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
MX2019010874A 2017-03-14 2018-03-13 Combinacion farmaceutica que comprende ponesimod. MX390941B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2017055994 2017-03-14
PCT/EP2018/056185 WO2018167030A1 (en) 2017-03-14 2018-03-13 Pharmaceutical combination comprising ponesimod

Publications (2)

Publication Number Publication Date
MX2019010874A MX2019010874A (es) 2019-12-11
MX390941B true MX390941B (es) 2025-03-21

Family

ID=61655772

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010874A MX390941B (es) 2017-03-14 2018-03-13 Combinacion farmaceutica que comprende ponesimod.

Country Status (24)

Country Link
US (2) US11723896B2 (OSRAM)
EP (1) EP3595657A1 (OSRAM)
JP (3) JP7281406B2 (OSRAM)
KR (1) KR102574562B1 (OSRAM)
CN (1) CN110381942B (OSRAM)
AU (2) AU2018233109B2 (OSRAM)
BR (1) BR112019018894A2 (OSRAM)
CA (1) CA3056301C (OSRAM)
CL (1) CL2019002525A1 (OSRAM)
CO (1) CO2019008510A2 (OSRAM)
CR (1) CR20190464A (OSRAM)
DO (1) DOP2019000257A (OSRAM)
EA (1) EA201992117A1 (OSRAM)
EC (1) ECSP19073317A (OSRAM)
IL (1) IL269239B2 (OSRAM)
JO (1) JOP20190207A1 (OSRAM)
MA (1) MA49822A (OSRAM)
MX (1) MX390941B (OSRAM)
NI (1) NI201900092A (OSRAM)
PE (1) PE20191489A1 (OSRAM)
PH (1) PH12019502110A1 (OSRAM)
SG (1) SG11201907308UA (OSRAM)
UA (1) UA125756C2 (OSRAM)
WO (1) WO2018167030A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190207A1 (ar) * 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES448386A1 (es) 1975-06-05 1978-04-16 Hoechst Ag Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico.
DE2854439A1 (de) 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
DE60110043T2 (de) * 2000-02-15 2006-03-02 Teva Pharmaceutical Industries Ltd. Methode zur synthetisierung von leflunomid
GB0123571D0 (en) * 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
SI1381356T1 (sl) * 2001-04-05 2008-12-31 Aventis Pharma Inc Uporaba (Z)-2-ciano-3-hidroksi-but-2-enojska kislina-(4'-trifluorometilfenil)-amida za zdravljenje multiple skleroze
US6894184B2 (en) 2003-03-18 2005-05-17 Aventis Pharma Deutschland Gmbh Process for preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides
CA2545582C (en) 2003-11-21 2013-04-16 Actelion Pharmaceuticals Ltd 5-(benz-(z)-ylidene)-thiazolidin-4-one derivatives as immunosuppressant agents
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
MX2007004265A (es) 2004-10-19 2008-03-04 Aventis Pharma Inc Uso de (4'trifluorometilfenil) -amida del acido (z) - 2 - ciano - 3 - hidroxi-but - 2- enoico para tratar la enfermedad inflamatoria del intestino.
DE102006017896A1 (de) 2006-04-13 2007-10-25 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Leflunomid enthaltende pharmazeutische Zusammensetzungen
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
CN101541772B (zh) 2006-11-23 2013-04-17 埃科特莱茵药品有限公司 一种制备2-亚氨基-四氢噻唑-4-酮衍生物的新方法
PT2278960T (pt) 2008-03-17 2017-03-09 Actelion Pharmaceuticals Ltd Regime de dosagem para um agonista seletivo do recetor s1p1
GB0819182D0 (en) 2008-10-20 2008-11-26 Actelion Pharmaceuticals Ltd Crystalline forms
UA107582C2 (uk) 2009-09-18 2015-01-26 Таблетований препарат (4'-трифторметилфеніл)аміду (z)-2-ціано-гідроксибут-2-еноєвої кислоти з поліпшеною стійкістю
WO2012015758A2 (en) 2010-07-30 2012-02-02 Saint Louis University Methods of treating pain
AR082436A1 (es) 2010-08-02 2012-12-05 Sanofi Aventis Us Llc Uso de teriflunomida para tratar la esclerosis multiple
EP2692343A1 (en) 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
RS60408B1 (sr) 2012-08-17 2020-07-31 Actelion Pharmaceuticals Ltd Postupak za pripremanje (2z,5z)-5-(3-hloro-4-((r)-2,3-dihidroksipropoksi)benziliden)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona i međujedinjenja upotrebljena u pomenutom postupku
WO2016079687A1 (en) 2014-11-18 2016-05-26 Lupin Limited Oral pharmaceutical composition of teriflunomide
SI3256125T1 (sl) 2014-12-11 2022-04-29 Actelion Pharmaceuticals Ltd Režim odmerjanja ponesimoda, selektivnega agonista receptorja S1P1
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
CN107920991A (zh) 2015-06-18 2018-04-17 马丁尼斯生物制药纳米技术公司 治疗炎性疾病或病状的组合物和方法
JOP20190207A1 (ar) * 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود

Also Published As

Publication number Publication date
CR20190464A (es) 2019-11-26
PE20191489A1 (es) 2019-10-21
CN110381942A (zh) 2019-10-25
AU2023274118B2 (en) 2024-12-12
MX2019010874A (es) 2019-12-11
NI201900092A (es) 2020-03-11
JP2020510045A (ja) 2020-04-02
CA3056301A1 (en) 2018-09-20
KR102574562B1 (ko) 2023-09-04
AU2018233109A1 (en) 2019-08-22
JP2024096962A (ja) 2024-07-17
IL269239B2 (en) 2023-07-01
MA49822A (fr) 2020-06-17
AU2023274118A1 (en) 2023-12-21
CA3056301C (en) 2024-10-01
US11723896B2 (en) 2023-08-15
CN110381942B (zh) 2022-12-27
ECSP19073317A (es) 2019-11-30
IL269239A (en) 2019-11-28
JOP20190207A1 (ar) 2019-09-10
US20200069655A1 (en) 2020-03-05
EA201992117A1 (ru) 2020-02-17
AU2018233109B2 (en) 2023-09-28
JP7281406B2 (ja) 2023-05-25
SG11201907308UA (en) 2019-09-27
BR112019018894A2 (pt) 2020-04-14
JP2023030091A (ja) 2023-03-07
IL269239B1 (en) 2023-03-01
PH12019502110A1 (en) 2020-03-16
EP3595657A1 (en) 2020-01-22
CO2019008510A2 (es) 2019-10-21
KR20190122716A (ko) 2019-10-30
UA125756C2 (uk) 2022-06-01
DOP2019000257A (es) 2020-09-15
WO2018167030A1 (en) 2018-09-20
CL2019002525A1 (es) 2020-02-07
US20240139161A1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
PH12019502110A1 (en) Pharmaceutical combination comprising ponesimod
MX2023011657A (es) Composiciones que comprenden curones y usos de los mismos.
ECSP19057403A (es) Usos terapéuticos de un polvo de insectos
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
MX391533B (es) Composiciones de saponinas y extractos vegetales.
JOP20190262B1 (ar) مثبطات بيرازول magl
MX2018009861A (es) Compuesto novedoso de tiofeno 2,3,5-sustituido como inhibidor de la proteina cinasa.
MX383931B (es) Compuestos de aza-piridona y usos de estos.
UY37342A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
EP3731832A4 (en) CANNABINOID DOSAGE FORM
EP3592377A4 (en) TISSUE KALLICREIN DOSAGE FORMS 1
MX2020006016A (es) Polimorfos.
UY37560A (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
IL285765A (en) Therapeutic uses of dulaglutide
MX2021004581A (es) Composiciones acuosas que comprenden omega nitrooxi-1-alcanoles.
MX376853B (es) Odorante osmanthus.
CO2019000596A2 (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
MX2014008336A (es) Combinacion farmacologica antihiperalgesica, antialodinica y antiinflamatoria, composiciones farmaceuticas que la contienen, y su uso para el tratamiento del dolor neuropatico.
CO2019007261A2 (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
MX378539B (es) Analagos de apelina ciclicos.
EA201990162A1 (ru) Фармацевтические композиции
MX2020004731A (es) Terapias de combinacion de inhibidor ezh2.
UA118382C2 (uk) Пероральна дозована форма ізосорбіду динітрату
UA120448U (uk) Фунгіцидна композиція
BR112019001976A2 (pt) inibidores da diacilglicerol aciltransferase 2